Lung Cancer Screening

Deffebach, Mark; Humphrey, Linda L.

doi:10.1016/j.suc.2015.05.006

Cited by 21 publications

(22 citation statements)

References 55 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NSCLC is further histologically subdivided into four categories: (a) lung adenocarcinoma (LAC); (b) squamous cell carcinoma; (c) large cell carcinoma; and (d) others. Of those, LAC is the most common type, and is responsible for more than 500 000 deaths in the world each year because it is often diagnosed at an advanced stage .Thus, an early diagnosis appears to be a promising measure for improving the prognoses of patients with LAC . Therefore, the identification of ideal molecular diagnostic markers for early detection of LAC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are associated with cancer progression and metastasis, although little is known about their role in lung adenocarcinoma (LAC). In the present study, microarrays were first used to screen for tumour-specific circRNA candidates in LAC tissue. Thirty-nine circRNAs were found to be up-regulated and 20 were down-regulated (fold change > 2.0). Among them, hsa_circ_0013958 was further confirmed to be up-regulated in all of the LAC tissues, cells and plasma. In addition, hsa_ circ_0013958 levels were associated with TNM stage (P = 0.009) and lymphatic metastasis (P = 0.006). The area under the receiver operating characteristic curve was 0.815 (95% confidence interval = 0.727-0.903; P < 0.001). In addition, to further illustrate the bioactivities of hsa_ circ_0013958 in LAC, siRNA-mediated inhibition of hsa_circ_0013958 was performed in vitro. The results showed that hsa_circ_0013958 promoted cell proliferation and invasion and inhibited cell apoptosis in LAC. Moreover, hsa_circ_0013958 was identified as a sponge of miR-134, and thus it upregulated oncogenic cyclin D1, which plays a pivotal role in the development of non-small cell lung cancer. In conclusion, our results suggested that hsa_circ_0013958 could be used as a potential non-invasive biomarker for the early detection and screening of LAC.

show abstract

Section: Introductionmentioning

confidence: 99%

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The trial was a success in terms of documenting a statistically signifi cant mortality reduction associated with screening. However, there are signifi cant challenges in implementing eff ective screening programs, including variable access to the technology and clinical expertise needed for screening [12,29]. Screening should also be coupled with interventions for tobacco cessation, which can greatly reduce the risk of lung cancer and other life-threatening conditions.…”

Section: Breast Cancermentioning

confidence: 99%

Cancer Prevention and Control: Then and Now

Ganz¹

2018

NAM Perspectives

View full text Add to dashboard Cite

“…The results of the landmark National Lung Screening Trial (NLST) published in 2011 [6], demonstrated a statistically significant mortality benefit of low-dose computed tomography (LDCT) over chest radiography (CXR) screening in high-risk individuals (defined by age and history of heavy smoking). This evidence and a systematic review of LDCT screening studies [7], prompted the American Cancer Society and other health care organizations to issue guidelines for clinicians to discuss lung cancer screening by LDCT with older patients with a history of heavy smoking, along with smoking-cessation counseling [8, 9]. …”

Section: Recent Advances In Lung Cancer Detection Reveal Unmet Clinicmentioning

confidence: 99%

Integration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer

Robles

Harris

2017

Lung Cancer

View full text Add to dashboard Cite

More than half of all new lung cancer diagnoses are made in patients with locally advanced or metastatic disease, at which point therapeutic options are scarce. It is anticipated, however, that the widespread use of Low-Dose Computed Tomography (LDCT) screening, will lead to a greater proportion of lung cancers being diagnosed at an early, operable, stage. Still, the overall rate of recurrence for surgically treated Stage I lung cancer patients is up to 30% within 5 years of diagnosis. Thus, the identification and clinical application of biomarkers of early stage lung cancer is a pressing medical need. The integrative analysis of “omic,” clinical and epidemiological data for single patients is a core principle of precision medicine. Through rigorous bioinformatics and statistical analyses we have identified biomarkers of early-stage lung cancer based on DNA methylation, expression of mRNA and miRNA, inflammatory cytokines, and urinary metabolites. Beyond a more comprehensive understanding of the molecular taxonomy of lung cancer, these biomarkers can have very practical implications in the context of unmet clinical needs of early stage lung cancer patients: First, current guidelines for LDCT screening broadly include individuals based on age and history of heavy smoking. Tumor-derived circulating biomarkers in the blood and urine associated with lung cancer risk could narrow and prioritize individuals for LDCT screening. Second, a high number of nodules are identified by LDCT, of which fewer than 5% are finally diagnosed as lung cancer. Biomarkers may help discriminate malignant nodules from benign or indolent lesions. Third, the expected rise in the numbers of lung cancer patients diagnosed at an early stage will necessitate new treatment options. Circulating, urinary and tissue-based biomarkers that molecularly categorize Stage I patients after tumor resection can help identify high-risk patients who may benefit from adjuvant chemotherapy or innovative immunotherapy regimens.

show abstract

Lung Cancer Screening

Cited by 21 publications

References 55 publications

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

Cancer Prevention and Control: Then and Now

Integration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer

Contact Info

Product

Resources

About